Another Canadian cannabis producer has announced the launch of more products into the growing medical cannabis market in Germany.

Canopy Growth Corporation has now officially launched its Tweed brand in Germany, including the availability of four new cultivars grown in the EU through an agreement with Gro-Vida S.A, a Portuguese medical cannabis cultivator.

Authorized medical patients in Germany will be able to access Jack Herer, a new sativa-dominant cultivar; Balanced Caramel and Wappa, two indica-prominent strains; and Gelato 33, a balanced hybrid strain. 

This builds on Tweed’s initial introduction of Glitter Bomb, an indica-dominant high THC strain, to the German medical market earlier in December 2024. That happened through an agreement with Cansativa GmbH (Cansativa), a vertically integrated German cannabis cultivator and distributor.

In addition to its flagship operations in Canada, Canopy Growth has a presence in Australia, Germany, Poland, and other specific international markets. The company also produces, distributes, and sells vaporizers and similar cannabis accessories in various global markets, including the United States. 

In its most recent quarterly report, for the three months ending December 31, 2024, Canopy’s international market net revenue increased 14% year-over-year, with strong growth in Poland and Germany. This growth was partially offset by a decline in Australian medical cannabis sales and the exit of US CBD sales earlier this fiscal year.

“As a leader in medical cannabis, Canopy Growth is expanding its German product lineup with the launch of the Tweed brand as well as new genetics to meet the growing needs of patients and healthcare practitioners,” said Luc Mongeau, Canopy Growth’s new CEO. 

“Through strategic agreements with EU-based cultivators and continued supply from our EU-GMP facility in Canada, Canopy Growth is focused on delivering a consistent, reliable flower supply enabling healthcare practitioners to confidently prescribe Tweed for patients across Germany.”

According to the Canadian government, exports of cannabis for medical purposes have continued to show significant increases in recent years. In the first six months of 2024, 67,475.28 kilograms of dried cannabis were exported to the international market, and in 2023, 79,279.75 kilograms were exported.

Australia received the most—3,512.5 kilograms, a 5% year-over-year increase. Germany was second with 1,546.2 kg, down by 27% year-over-year. Czechia was third, followed by Israel, Portugal, the Netherlands, and the UK.

While Germany’s medical cannabis market has been growing, with two of three production licences in the country going to Canadian companies Aurora Cannabis and Aphria, the recently-elected Conservative government has promised to push back on Germany’s cannabis laws. What that means for the country’s growing medical cannabis space is uncertain. 

Finn Haensel, CEO and Founder of Berline-based Sanity Group, an EU-based cannabis company, told StratCann recently that he is confident the Conservative government won’t touch medical cannabis, 

“If you read publicly what they are saying, they don’t differentiate, they just say cannabis,” said Haensel. “But we talked a lot with politicians over the last six months. We had very good exchanges with the conservative politicians, and when you talk to them, they say they only want to take back adult-use and don’t want to touch medical.”

In November, Tilray’s Aphria RX facility launched its first German-grown cannabis. In January, Aurora also announced the launch of its first cannabis brand in Germany under a new cultivation license. The German company Demecan is also licensed for production in the country.

In February 2024, Germany passed the German Medical Cannabis Act, expanding the country’s medical cannabis laws.

Germany is also a gateway into the expanding European market and is the largest medical cannabis market in Europe, with a population of 83 million, more than double that of Canada.  

Other European countries, including Switzerland, Spain, France, the Czech Republic, Malta, the Netherlands, and Ukraine, are also considering or are in the process of implementing various cannabis laws.

Germany legalized cannabis for non-medical purposes this past March, with the law coming into effect in stages. On April 1, personal possession and cultivation became legal. On July 1, the country began allowing cannabis growing clubs. However, the country does not allow the sale of cannabis except for non-medical purposes.

Related Articles

Wholesale flower prices expected to continue to rebound in 2025, domestic market will continue to slow

January 31, 2025

Increase in medical sales helps offset declines for Canopy in Q3 2025

February 7, 2025

What does the Conservative win mean for legal cannabis in Germany?

February 26, 2025